COVID-19 and Genitourinary Cancers Videos

COVID-19 and Genitourinary Cancers Videos

Search

The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin Details Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...
Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin Details Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (ENZAMET) - Tanya Dorff Details Tanya Dorff and Alicia Morgans discuss the ENZAMET (Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer) trial design and key take-home messages based upon the ASCO 2019 plenary presentation by Christopher Sweeney. The investigators hypothesized that adding enzalutamide to first-line therapy would delay the emergence of castration resistance and thereby improve o...
Impact of Academic Collaborations in mHSPC Trial: ENZAMET - Chris Sweeney Details Chris Sweeney and Alicia Morgans discuss how the academic collaboration for ENZAMET (Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer) became a reality and initiated in November 2014. The ENZAMET study was led by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. ENZAMET (ANZUP 1304) is a global collaborative investigator...
2019 ASCO: ENZAMET: Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer - Christopher Sweeney Details Chris Sweeney and Alicia Morgans discuss the interim analysis of the international academic investigator-sponsored, randomized phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer who received the nonsteroidal antiandrogen agent enzalutamide along with standard-of-care treatment were alive after 3 years, compared with 72% of men who received other nonster...
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans Details Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. Dr. Morgans emphasizes how patients should be included in the conversations and the decisions on treatment selection and considerations on efficacy, safety, and potential toxicities. She reiterates that...